Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Continuing the multiple sclerosis risk sharing scheme is unjustified.

× No keyword cloud information.

10 in total

Review 1. Societal values in the allocation of healthcare resources: is it all about the health gain?

Authors: Tania Stafinski; Devidas Menon; Deborah Marshall; Timothy Caulfield
Journal: Patient Date: 2011 Impact factor: 3.883

Review 2. Health technology funding decision-making processes around the world: the same, yet different.

Authors: Tania Stafinski; Devidas Menon; Donald J Philippon; Christopher McCabe
Journal: Pharmacoeconomics Date: 2011-06 Impact factor: 4.981

3. Multiple sclerosis: relapses, resource use, and costs.

Authors: A J Hawton; C Green
Journal: Eur J Health Econ Date: 2015-10-05

Review 4. Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.

Authors: Babak Soleimani; Katy Murray; David Hunt
Journal: Drug Saf Date: 2019-08 Impact factor: 5.606

5. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?

Authors: Adrian Towse
Journal: Br J Clin Pharmacol Date: 2010-09 Impact factor: 4.335

6. Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine.

Authors: Heleen Vellekoop; Simone Huygens; Matthijs Versteegh; László Szilberhorn; Tamás Zelei; Balázs Nagy; Rositsa Koleva-Kolarova; Apostolos Tsiachristas; Sarah Wordsworth; Maureen Rutten-van Mölken
Journal: Pharmacoeconomics Date: 2021-04-16 Impact factor: 4.981

Review 7. Development of oral immunomodulatory agents in the management of multiple sclerosis.

Authors: Richard Nicholas; Paolo Giannetti; Ali Alsanousi; Tim Friede; Paolo A Muraro
Journal: Drug Des Devel Ther Date: 2011-05-10 Impact factor: 4.162

8. Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.

Authors: Liz Morrell; Sarah Wordsworth; Anna Schuh; Mark R Middleton; Sian Rees; Richard W Barker
Journal: BMC Health Serv Res Date: 2018-05-31 Impact factor: 2.655

9. Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.

Authors: David Yamamoto; Jonathan D Campbell
Journal: Autoimmune Dis Date: 2012-12-06

Review 10. Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years.

Authors: Annie Hawton; Elizabeth Goodwin; Kate Boddy; Jennifer Freeman; Sarah Thomas; Jeremy Chataway; Colin Green
Journal: Mult Scler Date: 2020-09-03 Impact factor: 6.312

10 in total